Search
-
Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
Media
Discussions relate to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system
https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-in-advanced-discussions-with-european-union-to-supply-up-to-300-million-doses-of-covid-19-vaccine/
First published: 31 July 2020
-
Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
Media
Agreement relates to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.
https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-agree-with-the-uk-government-to-supply-up-to-60-million-doses-of-covid-19-vaccine/
First published: 29 July 2020
-
Updated List Of Vaccines HK Macau 2022
Media
https://www.gsk.com/media/9699/updated-list-of-vaccines-hk-macau-2022.pdf
First published: 23 February 2023
-
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
Media
Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups.
https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-covid-19-vaccine-candidate-demonstrates-strong-immune-responses-across-all-adult-age-groups-in-phase-2-trial/
First published: 17 May 2021
-
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
Media
Sanofi and GSK today announce that they intend to submit data from both their booster and Phase 3 efficacy trials
https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-to-seek-regulatory-authorization-for-covid-19-vaccine/
First published: 23 February 2022
-
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease
Media
Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59.
https://www.gsk.com/en-gb/media/press-releases/new-data-for-arexvy-show-potential-to-help-protect-adults-aged-50-to-59/
First published: 25 October 2023
-
GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk
Media
Application supported by positive results of a Phase III study showing immune response and acceptable tolerability profile.
https://www.gsk.com/en-gb/media/press-releases/arexvy-accepted-for-regulatory-review-by-ema-for-prevention-of-rsv-in-adults-50-59/
First published: 29 January 2024
-
GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk
Media
GSK is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk.
https://www.gsk.com/en-gb/media/press-releases/arexvy-accepted-under-priority-review-in-us-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk/
First published: 06 February 2024
-
Japan’s Ministry of Health, Labour and Welfare approves GSK’s Arexvy, the country’s first respiratory syncytial virus (RSV) vaccine for older adults
Media
Arexvy’s approval will help protect adults 60 years of age and older in Japan from RSV disease for the first time
https://www.gsk.com/en-gb/media/press-releases/japan-s-ministry-of-health-labour-and-welfare-approves-gsk-s-arexvy/
First published: 25 September 2023
-
Japan’s Ministry of Health, Labour and Welfare accepts Arexvy (RSV vaccine) regulatory application to prevent RSV disease in adults aged 50-59 at increased risk
Media
Submission supported by positive results of a Phase III study showing immune response and safety in adults aged 50-59.
https://www.gsk.com/en-gb/media/press-releases/japan-accepts-arexvy-regulatory-application-to-prevent-rsv-disease-in-adults-aged-50-59/
First published: 12 December 2023